Trial site
Icr Medical S.L.
Madrid, 28002, SpainNot linked to an institution yet
The trials here
What the 11 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 25 trials
- Status
- Active, not recruiting6 trials
- Recruiting3 trials
- Not yet recruiting2 trials
- Lead sponsor
- Janssen Research & Development, LLC2 trials
- Oruka Therapeutics, Inc.2 trials
- AbbVie1 trial
- Almirall, S.A.1 trial
- Apogee Therapeutics Inc.1 trial
- and 4 more
Running trials
Recruiting
A Phase 3 Mechanistic Longitudinal Study to Evaluate the Impact of EARLY Risankizumab Treatment on TRM Cell Levels in Moderate-to-Severe Psoriasis
2025-521424-30-00· Phase 3· Icr Medical S.L.· Source
Recruiting
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07690371· Phase 3· Nektar Therapeutics· Source
Recruiting
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
NCT07449702· Phase 2· Oruka Therapeutics, Inc.· Source
Recruiting
A Study of LAD603 in Adults With Alopecia Areata
NCT07311564· Phase 2· Almirall, S.A.· Source
Active, not recruiting
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07290569· Phase 2· Oruka Therapeutics, Inc.· Source
Recruiting
A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis
2024-519795-11-00· Phase 2· Apogee Therapeutics Inc.· Source
Active, not recruiting
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948· Phase 2· Apogee Therapeutics, Inc.· Source
Recruiting
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
2023-505121-14-00· Phase 3· Janssen - Cilag International· Source
Active, not recruiting
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411· Phase 3· AbbVie· Source
Active, not recruiting
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115· Phase 3· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error